AnaptysBio Net Worth
AnaptysBio Net Worth Breakdown | ANAB |
AnaptysBio Net Worth Analysis
AnaptysBio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AnaptysBio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AnaptysBio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AnaptysBio's net worth analysis. One common approach is to calculate AnaptysBio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AnaptysBio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AnaptysBio's net worth. This approach calculates the present value of AnaptysBio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AnaptysBio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AnaptysBio's net worth. This involves comparing AnaptysBio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AnaptysBio's net worth relative to its peers.
To determine if AnaptysBio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AnaptysBio's net worth research are outlined below:
| AnaptysBio generated a negative expected return over the last 90 days | |
| AnaptysBio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 17.16 M. Net Loss for the year was (163.62 M) with loss before overhead, payroll, taxes, and interest of (78.51 M). | |
| AnaptysBio currently holds about 442.15 M in cash with (120.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: AnaptysBio reports failed Phase 2B trial, maintains cash reserves |
AnaptysBio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AnaptysBio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AnaptysBio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know AnaptysBio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AnaptysBio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AnaptysBio backward and forwards among themselves. AnaptysBio's institutional investor refers to the entity that pools money to purchase AnaptysBio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Assenagon Asset Management Sa | 2024-09-30 | 475.4 K | Geode Capital Management, Llc | 2024-09-30 | 465.4 K | Woodline Partners Lp | 2024-09-30 | 460 K | 5am Venture Management, Llc | 2024-09-30 | 357.7 K | Franklin Resources Inc | 2024-09-30 | 354.4 K | Goldman Sachs Group Inc | 2024-09-30 | 350.4 K | Cormorant Asset Management, Llc | 2024-09-30 | 342.5 K | Millennium Management Llc | 2024-09-30 | 331.6 K | Federated Hermes Inc | 2024-09-30 | 317.2 K | Ecor1 Capital, Llc | 2024-09-30 | 7.8 M | Fmr Inc | 2024-09-30 | 3.3 M |
Follow AnaptysBio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 702.6 M.Market Cap |
|
Project AnaptysBio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (1.86) | (1.95) |
When accessing AnaptysBio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AnaptysBio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AnaptysBio's profitability and make more informed investment decisions.
Please note, the presentation of AnaptysBio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.
Evaluate AnaptysBio's management efficiency
AnaptysBio has return on total asset (ROA) of (0.1785) % which means that it has lost $0.1785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6182) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 12, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, AnaptysBio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.5 M, whereas Total Assets are forecasted to decline to about 354.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.27 | 3.11 | |
| Tangible Book Value Per Share | 3.27 | 3.11 | |
| Enterprise Value Over EBITDA | (3.90) | (4.10) | |
| Price Book Value Ratio | 6.55 | 6.22 | |
| Enterprise Value Multiple | (3.90) | (4.10) | |
| Price Fair Value | 6.55 | 6.22 |
Evaluating the management effectiveness of AnaptysBio allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The AnaptysBio Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 5.0545 | Revenue 57.2 M | Quarterly Revenue Growth 8.047 | Revenue Per Share 2.086 | Return On Equity (1.62) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AnaptysBio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AnaptysBio Corporate Filings
8K | 11th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 15th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
AnaptysBio Earnings per Share Projection vs Actual
AnaptysBio Corporate Management
| Martin Dahl | Senior Research | Profile | |
| Monique Silva | Senior Affairs | Profile | |
| James MD | Advisor | Profile | |
| Beth Mueller | Senior Resources | Profile | |
| Priya Raina | Senior Operations | Profile | |
| FAAD MBA | Chief Officer | Profile | |
| Daniel Faga | Interim Director | Profile |
Already Invested in AnaptysBio?
The danger of trading AnaptysBio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AnaptysBio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AnaptysBio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AnaptysBio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 2.086 | Quarterly Revenue Growth 8.047 | Return On Assets (0.18) | Return On Equity (1.62) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.